Cargando…
Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza
BACKGROUND: Antibody-based therapies for respiratory viruses are of increasing importance. The INSIGHT 006 trial administered anti-influenza hyperimmune intravenous immunoglobulin (Flu-IVIG) to patients hospitalized with influenza. Flu-IVIG treatment improved outcomes in patients with influenza B bu...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443807/ https://www.ncbi.nlm.nih.gov/pubmed/37289541 http://dx.doi.org/10.1172/jci.insight.167464 |
_version_ | 1785093915355906048 |
---|---|
author | Vanderven, Hillary A. Wentworth, Deborah N. Han, Win Min Peck, Heidi Barr, Ian G. Davey, Richard T. Beigel, John H. Dwyer, Dominic E. Jain, Mamta K. Angus, Brian Brandt, Christian T. Mykietiuk, Analia Law, Matthew G. Neaton, James D. Kent, Stephen J. |
author_facet | Vanderven, Hillary A. Wentworth, Deborah N. Han, Win Min Peck, Heidi Barr, Ian G. Davey, Richard T. Beigel, John H. Dwyer, Dominic E. Jain, Mamta K. Angus, Brian Brandt, Christian T. Mykietiuk, Analia Law, Matthew G. Neaton, James D. Kent, Stephen J. |
author_sort | Vanderven, Hillary A. |
collection | PubMed |
description | BACKGROUND: Antibody-based therapies for respiratory viruses are of increasing importance. The INSIGHT 006 trial administered anti-influenza hyperimmune intravenous immunoglobulin (Flu-IVIG) to patients hospitalized with influenza. Flu-IVIG treatment improved outcomes in patients with influenza B but showed no benefit for influenza A. METHODS: To probe potential mechanisms of Flu-IVIG utility, sera collected from patients hospitalized with influenza A or B viruses (IAV or IBV) were analyzed for antibody isotype/subclass and Fcγ receptor (FcγR) binding by ELISA, bead-based multiplex, and NK cell activation assays. RESULTS: Influenza-specific FcγR-binding antibodies were elevated in Flu-IVIG–infused IBV- and IAV-infected patients. In IBV-infected participants (n = 62), increased IgG3 and FcγR binding were associated with more favorable outcomes. Flu-IVIG therapy also improved the odds of a more favorable outcome in patients with low levels of anti-IBV Fc-functional antibody. Higher FcγR-binding antibody was associated with less favorable outcomes in IAV-infected patients (n = 50), and Flu-IVIG worsened the odds of a favorable outcome in participants with low levels of anti-IAV Fc-functional antibody. CONCLUSION: These detailed serological analyses provide insights into antibody features and mechanisms required for a successful humoral response against influenza, suggesting that IBV-specific, but not IAV-specific, antibodies with Fc-mediated functions may assist in improving influenza outcome. This work will inform development of improved influenza immunotherapies. TRIAL REGISTRATION: ClinicalTrials.gov NCT02287467. FUNDING: Funding for this research was provided by subcontract 13XS134 under Leidos Biomedical Research Prime Contract HHSN261200800001E and HHSN261201500003I, NCI/NIAID. |
format | Online Article Text |
id | pubmed-10443807 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society for Clinical Investigation |
record_format | MEDLINE/PubMed |
spelling | pubmed-104438072023-08-23 Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza Vanderven, Hillary A. Wentworth, Deborah N. Han, Win Min Peck, Heidi Barr, Ian G. Davey, Richard T. Beigel, John H. Dwyer, Dominic E. Jain, Mamta K. Angus, Brian Brandt, Christian T. Mykietiuk, Analia Law, Matthew G. Neaton, James D. Kent, Stephen J. JCI Insight Clinical Medicine BACKGROUND: Antibody-based therapies for respiratory viruses are of increasing importance. The INSIGHT 006 trial administered anti-influenza hyperimmune intravenous immunoglobulin (Flu-IVIG) to patients hospitalized with influenza. Flu-IVIG treatment improved outcomes in patients with influenza B but showed no benefit for influenza A. METHODS: To probe potential mechanisms of Flu-IVIG utility, sera collected from patients hospitalized with influenza A or B viruses (IAV or IBV) were analyzed for antibody isotype/subclass and Fcγ receptor (FcγR) binding by ELISA, bead-based multiplex, and NK cell activation assays. RESULTS: Influenza-specific FcγR-binding antibodies were elevated in Flu-IVIG–infused IBV- and IAV-infected patients. In IBV-infected participants (n = 62), increased IgG3 and FcγR binding were associated with more favorable outcomes. Flu-IVIG therapy also improved the odds of a more favorable outcome in patients with low levels of anti-IBV Fc-functional antibody. Higher FcγR-binding antibody was associated with less favorable outcomes in IAV-infected patients (n = 50), and Flu-IVIG worsened the odds of a favorable outcome in participants with low levels of anti-IAV Fc-functional antibody. CONCLUSION: These detailed serological analyses provide insights into antibody features and mechanisms required for a successful humoral response against influenza, suggesting that IBV-specific, but not IAV-specific, antibodies with Fc-mediated functions may assist in improving influenza outcome. This work will inform development of improved influenza immunotherapies. TRIAL REGISTRATION: ClinicalTrials.gov NCT02287467. FUNDING: Funding for this research was provided by subcontract 13XS134 under Leidos Biomedical Research Prime Contract HHSN261200800001E and HHSN261201500003I, NCI/NIAID. American Society for Clinical Investigation 2023-07-24 /pmc/articles/PMC10443807/ /pubmed/37289541 http://dx.doi.org/10.1172/jci.insight.167464 Text en © 2023 Vanderven et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Clinical Medicine Vanderven, Hillary A. Wentworth, Deborah N. Han, Win Min Peck, Heidi Barr, Ian G. Davey, Richard T. Beigel, John H. Dwyer, Dominic E. Jain, Mamta K. Angus, Brian Brandt, Christian T. Mykietiuk, Analia Law, Matthew G. Neaton, James D. Kent, Stephen J. Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza |
title | Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza |
title_full | Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza |
title_fullStr | Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza |
title_full_unstemmed | Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza |
title_short | Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza |
title_sort | understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (flu-ivig) for severe human influenza |
topic | Clinical Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443807/ https://www.ncbi.nlm.nih.gov/pubmed/37289541 http://dx.doi.org/10.1172/jci.insight.167464 |
work_keys_str_mv | AT vandervenhillarya understandingthetreatmentbenefitofhyperimmuneantiinfluenzaintravenousimmunoglobulinfluivigforseverehumaninfluenza AT wentworthdeborahn understandingthetreatmentbenefitofhyperimmuneantiinfluenzaintravenousimmunoglobulinfluivigforseverehumaninfluenza AT hanwinmin understandingthetreatmentbenefitofhyperimmuneantiinfluenzaintravenousimmunoglobulinfluivigforseverehumaninfluenza AT peckheidi understandingthetreatmentbenefitofhyperimmuneantiinfluenzaintravenousimmunoglobulinfluivigforseverehumaninfluenza AT barriang understandingthetreatmentbenefitofhyperimmuneantiinfluenzaintravenousimmunoglobulinfluivigforseverehumaninfluenza AT daveyrichardt understandingthetreatmentbenefitofhyperimmuneantiinfluenzaintravenousimmunoglobulinfluivigforseverehumaninfluenza AT beigeljohnh understandingthetreatmentbenefitofhyperimmuneantiinfluenzaintravenousimmunoglobulinfluivigforseverehumaninfluenza AT dwyerdominice understandingthetreatmentbenefitofhyperimmuneantiinfluenzaintravenousimmunoglobulinfluivigforseverehumaninfluenza AT jainmamtak understandingthetreatmentbenefitofhyperimmuneantiinfluenzaintravenousimmunoglobulinfluivigforseverehumaninfluenza AT angusbrian understandingthetreatmentbenefitofhyperimmuneantiinfluenzaintravenousimmunoglobulinfluivigforseverehumaninfluenza AT brandtchristiant understandingthetreatmentbenefitofhyperimmuneantiinfluenzaintravenousimmunoglobulinfluivigforseverehumaninfluenza AT mykietiukanalia understandingthetreatmentbenefitofhyperimmuneantiinfluenzaintravenousimmunoglobulinfluivigforseverehumaninfluenza AT lawmatthewg understandingthetreatmentbenefitofhyperimmuneantiinfluenzaintravenousimmunoglobulinfluivigforseverehumaninfluenza AT neatonjamesd understandingthetreatmentbenefitofhyperimmuneantiinfluenzaintravenousimmunoglobulinfluivigforseverehumaninfluenza AT kentstephenj understandingthetreatmentbenefitofhyperimmuneantiinfluenzaintravenousimmunoglobulinfluivigforseverehumaninfluenza AT understandingthetreatmentbenefitofhyperimmuneantiinfluenzaintravenousimmunoglobulinfluivigforseverehumaninfluenza |